Fluidigm gene sequencer
Fluidigm gene sequencer ()

SAN FRANCISCO — Attorneys from Wilson Sonsini Goodrich & Rosati and Latham & Watkins advised on genomics technology firm Fluidigm Corp.’s $208 million acquisition of DVS Sciences Inc., which makes a device used to analyze single cells in biological research.

The deal between the Bay Area companies is geared toward enhancing Fluidigm’s offerings at the single-cell level. Bringing together technologies pioneered by the two companies could “transform single-cell analysis for life sciences research, drug development, and potentially diagnostics,” said Dr. Scott Tanner, chief technology officer and co-founder of DVS.

The corporate team advising DVS is led from Latham’s Silicon Valley office by partner Mark Roeder, with associates Chad Rolston, Brian Cuneo, Charlotte Chang and Kathryn Boolukos. Latham partner James Metz in Silicon Valley and associate Michelle Khoury in Los Angeles provided counsel on employee benefits matters; partners Kirt Switzer and Grace Chen in San Francisco advised on tax matters with associate Rachel Burns in Silicon Valley; partner Joshua Holian in San Francisco advised on antitrust considerations; partner Judith Hasko and associate Kate Hillier in Silicon Valley advised on intellectual property matters; and partner William McGlone and associate Jeffrey Lord in Washington, D.C., handled regulatory matters.

The Wilson Sonsini deal team advising Fluidigm included partners Robert Ishii in San Francisco and Robert Kornegay in San Diego as well as associates Jason Skolnik in San Diego and Thomas O’Brien in Seattle.

The transaction is expected to close in February.

Contact the reporter at callison@alm.com.